An emergency care research study of bleeding in the brain
We need your input on an emergency care research study of bleeding in the brain.
About this research study:
FASTEST is a research study involving patients who have had bleeding in the brain, also called intracerebral hemorrhage (ICH).
ICH occurs when a weakened blood vessel in the brain breaks and bleeding accumulates in the brain. Most of this bleeding occurs within a few hours of onset of symptoms. The brain injury from ICH is usually very severe, over 40% of people with ICH die within a month, and only 20% can independently care for themselves after 6 months. There is currently no treatment for ICH that is scientifically proven to improve outcome. The FASTEST research study is being done to determine if recombinant Factor VIIa (rFVIIa), a protein that our body makes to stop bleeding at the site of injury to a blood vessel, can slow bleeding in the brain and improve outcome.
Additional Information
Temple University and Thomas Jefferson University are joining researchers at more than 100 other hospitals across the United States and other countries to conduct a research study of bleeding in the brain called FASTEST. This research study may affect you or someone you know, and we need to find out ahead of time what the community thinks about it. THANK YOU for your help and time in completing this survey.
rFVIIa is approved for treatment of bleeding in patients who have inherited lack of
clotting factors but is not approved for treatment of ICH.
Participants in the FASTEST research study are placed at random, that is by chance, into one of 2 groups. They have an equal chance of getting rFVIIa or placebo (no active ingredient). One group receives rFVIIa intravenously over 2 minutes within two hours of onset of symptoms and the other group receives placebo. We do not know if rFVIIa is better than placebo for patients with bleeding in the brain.
The results of the FASTEST research study will help doctors discover if rFVIIa improves outcome in patients with bleeding in the brain.
Medical care otherwise will be identical for the two treatment groups, including close management of blood pressure and care within an intensive care unit. Some patients will be enrolled without consent if a family member or representative is not rapidly available.
Before the research study starts, we will consult with the community.
clotting factors but is not approved for treatment of ICH.
Participants in the FASTEST research study are placed at random, that is by chance, into one of 2 groups. They have an equal chance of getting rFVIIa or placebo (no active ingredient). One group receives rFVIIa intravenously over 2 minutes within two hours of onset of symptoms and the other group receives placebo. We do not know if rFVIIa is better than placebo for patients with bleeding in the brain.
The results of the FASTEST research study will help doctors discover if rFVIIa improves outcome in patients with bleeding in the brain.
Medical care otherwise will be identical for the two treatment groups, including close management of blood pressure and care within an intensive care unit. Some patients will be enrolled without consent if a family member or representative is not rapidly available.
Before the research study starts, we will consult with the community.
There are no known risks involved in participating in this survey. Your participation in this survey is completely voluntary.